The presentation will be available on the Rectify website at https://rectifypharma.com/publications/.

Dr. Falk Pharma’s norucholic acid (NCA) drug has demonstrated potential in a Phase III trial for primary sclerosing ...

Dr Falk Pharma, a research-based pharmaceutical company specialising in digestive and metabolic medicine, has announced ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

Study results demonstrate superiority of norucholic acid (NCA) over placebo in the combined primary endpoint. There is ...

A copy of the R&D Day presentation can be found here. About Primary Sclerosing Cholangitis Primary Sclerosing Cholangitis (PSC) is a rare, progressive, cholestatic, immune‐mediated disease of ...

Ipsen’s elafibranor has shown promise as a treatment for primary sclerosing cholangitis (PSC), a rare liver disease that currently has no approved treatment options. Results from the phase 2 ELMWOOD ...

Objectives: To describe the occurrence of secondary sclerosing cholangitis in critically ill patients (SC-CIP) with febrile infection-related epilepsy syndrome (FIRES). Methods: Monocentric ...

A group dedicated to electing young progressives co-founded by David Hogg, the vice chair of the Democratic National Committee, is launching a $20 million effort to primary “out-of-touch, ...

primary sclerosing cholangitis, and obstructive biliary disease. It also occurs with cancer of the head of the pancreas, hepatitis, and drug-induced liver disease. However, it is less common with ...

Primary biliary cholangitis (PBC) is an autoimmune disorder that leads to the destruction of bile ducts within the liver. As more bile ducts become lost and damaged, bile acids build up within the ...